A Phase 1 interventional study of Pirtobrutinib and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib. The study will also evaluate the safety and tolerability of pirtobrutinib. The study will last up to 71 days, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pirtobrutinib a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
Drug: Pirtobrutinib
Placebo (matched to Pirtobrutinib) a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
Drug: Placebo
Moxifloxacin a single oral dose on Day 1, 12 and 23 following a fast of at least 8 hours prior to and 6 hours after dosing.
Drug: Moxifloxacin
Administered orally
Also known as: LOXO-305, LY3527727
Administered orally
Administered orally
Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF)
The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.
Time frame: Baseline (Predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Change From Baseline in (Δ) QTcF
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Change from baseline in (Δ) QTcF was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Change From Baseline in Heart Rate (ΔHR)
Heart rate is the number of times the ventricles of the heart contract and relax per minute. Change from baseline in heart rate (ΔHR) was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Change From Baseline in Pulse Rate (ΔPR)
Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Change From Baseline in QRS Intervals (Δ QRS)
QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Change from baseline in QRS intervals (Δ QRS) was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔQTcS), If a Substantial Heart Rate Effect Was Observed
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔQTcI), If a Substantial Heart Rate Effect Was Observed
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Placebo-corrected Change From Baseline in Heart Rate (ΔΔHR)
Heart rate is the number of times the ventricles of the heart contract and relax per minute. Placebo-corrected change from baseline in heart rate (ΔΔHR) was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Placebo-corrected Change From Baseline in Pulse Rate (ΔΔ PR)
Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Placebo-corrected change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Placebo-Corrected Change From Baseline in QRS (ΔΔQRS)
QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Placebo-corrected change from baseline in QRS intervals (ΔΔQRS) was calculated using linear mixed-effects model analysis.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Placebo-corrected Change From Baseline in ΔQTcF (ΔΔQTcF), If a Substantial Heart Rate Effect Was Observed
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Placebo-corrected Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔΔQTcS), If a Substantial Heart Rate Effect Was Observed
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Placebo-corrected Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔΔQTcI), If a Substantial Heart Rate Effect Was Observed
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.
Time frame: Baseline (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12 and 24 hours post-dose
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Changes
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with potentially clinically significant ECG changes were reported.
Time frame: Baseline up to Day 33
Number of Participants With Treatment Emergent Changes in T-wave Morphology and U-wave Presence
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with treatment emergent changes in T-wave morphology and U-wave presence were reported.
Time frame: Baseline up to Day 33
Pharmacokinetic (PK): Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Pirtobrutinib
PK: %AUCextrap was defined as percentage extrapolation for AUC0-inf.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Mean Residence Time (MRT) of Pirtobrutinib
PK: MRT was calculated by the area under the first moment curve divided by the area under the concentration time curve.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib
PK: Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
PK: Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for pirtobrutinib.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib
PK: t1/2 was defined as the terminal elimination phase half-life for pirtobrutinib.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib
PK: Cmax was defined as the maximum plasma concentration for pirtobrutinib.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
PK: AUC(0-24) was defined as the area under the plasma concentration-time curve from 0 time to 24 hours post-dose.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24 hours post-dose
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
PK: AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for pirtobrutinib.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
PK: Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib
PK: AUC(0-inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for pirtobrutinib.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
PK: Apparent Terminal Elimination Rate Constant (λZ) of Pirtobrutinib
PK: Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8.5, 12, 24, 48, 72, and 96 hours post-dose
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: BCA | Treatment Sequence 3: CAB | Treatment Sequence 4: ACB | Treatment Sequence 5: CBA | Treatment Sequence 6: BAC |
|---|---|---|---|---|---|---|
| Started | 5 | 6 | 5 | 5 | 5 | 5 |
| Received 1 dose of treatment a | 5 | 5 | 5 | 5 | 5 | 5 |
| Received 1 dose of treatment b | 5 | 6 | 5 | 5 | 5 | 5 |
| Received 1 dose of treatment c | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: BCA | Treatment Sequence 3: CAB | Treatment Sequence 4: ACB | Treatment Sequence 5: CBA | Treatment Sequence 6: BAC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: BCA | Treatment Sequence 3: CAB | Treatment Sequence 4: ACB | Treatment Sequence 5: CBA | Treatment Sequence 6: BAC |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The cardiodynamic assessment was performed through 12-lead electrocardiogram (ECG) extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Placebo-corrected change from baseline in QTcF (ΔΔQTcF) was calculated based on model-predicted effect.
| milliseconds (msec) | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) | 0.73 (-1.17 to 2.64) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF. Change from baseline in (Δ) QTcF was calculated using linear mixed-effects model analysis.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo | Treatment C: 400 mg Moxifloxacin |
|---|---|---|---|
| Change at 0.25 hour post-dose | -0.4 (-1.41 to 0.68) | 0.0 (-1.01 to 1.08) | -0.1 (-1.15 to 0.97) |
| Change at 0.5 hour post-dose | -4.5 (-5.94 to -3.06) | -2.8 (-4.21 to -1.33) | 4.2 (2.72 to 5.66) |
| Change at 0.75 hour post-dose | -3.8 (-5.37 to -2.29) | -2.0 (-3.50 to -0.42) | 7.6 (6.03 to 9.17) |
| Change at 1 hour post-dose | -2.8 (-4.25 to -1.33) | -1.2 (-2.65 to 0.24) | 8.3 (6.88 to 9.80) |
| Change at 1.5 hours post-dose | -0.6 (-2.26 to 0.98) | -1.0 (-2.63 to 0.61) | 9.8 (8.15 to 11.45) |
| Change at 2 hours post-dose | -2.2 (-3.89 to -0.49) | -1.1 (-2.80 to 0.60) | 9.4 (7.64 to 11.10) |
| Change at 2.5 hours post-dose | -0.2 (-1.89 to 1.46) | 0.2 (-1.45 to 1.90) | 10.1 (8.39 to 11.82) |
| Change at 3 hours post-dose | 0.3 (-1.45 to 2.13) | 0.5 (-1.26 to 2.32) | 9.9 (8.11 to 11.75) |
| Change at 4 hours post-dose | 2.2 (0.18 to 4.19) | 0.3 (-1.70 to 2.32) | 9.8 (7.78 to 11.86) |
| Change at 6 hours post-dose | 3.5 (1.48 to 5.42) | 0.9 (-1.08 to 2.86) | 9.3 (7.26 to 11.26) |
| Change at 8.5 hours post-dose | -5.1 (-7.07 to -3.09) | -5.2 (-7.15 to -3.17) | 2.8 (0.80 to 4.85) |
| Change at 12 hours post-dose | 1.2 (-1.41 to 3.75) | 0.6 (-1.99 to 3.17) | 6.8 (4.12 to 9.44) |
| Change at 24 hours post-dose | 0.0 (-1.71 to 1.69) | 0.6 (-1.11 to 2.41) | 5.0 (3.22 to 6.74) |
Heart rate is the number of times the ventricles of the heart contract and relax per minute. Change from baseline in heart rate (ΔHR) was calculated using linear mixed-effects model analysis.
| beats per minute (beats/min) | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Change at 0.25 hour post-dose | 0.1 (-0.94 to 1.07) | -0.9 (-1.81 to 0.09) |
| Change at 0.5 hour post-dose | -0.5 (-1.66 to 0.61) | -1.2 (-2.24 to -0.07) |
| Change at 0.75 hour post-dose | 0.0 (-1.28 to 1.23) | -0.4 (-1.66 to 0.76) |
| Change at 1 hour post-dose | 1.0 (-0.23 to 2.32) | -0.1 (-1.34 to 1.09) |
| Change at 1.5 hours post-dose | 0.9 (-0.28 to 2.06) | -1.7 (-2.82 to -0.58) |
| Change at 2 hours post-dose | 0.5 (-0.73 to 1.76) | -0.8 (-1.98 to 0.42) |
| Change at 2.5 hours post-dose | 2.2 (0.87 to 3.54) | -0.1 (-1.37 to 1.22) |
| Change at 3 hours post-dose | 1.3 (-0.01 to 2.52) | 0.4 (-0.84 to 1.60) |
| Change at 4 hours post-dose | 1.4 (0.12 to 2.67) | 0.4 (-0.85 to 1.61) |
| Change at 6 hours post-dose | 2.0 (0.65 to 3.43) | 0.5 (-0.88 to 1.82) |
| Change at 8.5 hours post-dose | 4.0 (2.42 to 5.59) | 3.4 (1.89 to 5.00) |
| Change at 12 hours post-dose | 2.0 (0.22 to 3.74) | 0.4 (-1.36 to 2.09) |
| Change at 24 hours post-dose | 1.2 (0.00 to 2.48) | 0.8 (-0.41 to 2.04) |
Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.
| beats per minute (beats/min) | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Change at 0.25 hour post-dose | -2.6 (-4.46 to -0.83) | -0.8 (-2.60 to 1.02) |
| Change at 0.5 hour post-dose | 0.3 (-1.61 to 2.15) | 1.5 (-0.42 to 3.34) |
| Change at 0.75 hour post-dose | 0.3 (-1.41 to 1.98) | 1.0 (-0.72 to 2.67) |
| Change at 1 hour post-dose | -0.1 (-2.24 to 2.11) | 0.7 (-1.48 to 2.83) |
| Change at 1.5 hours post-dose | -0.9 (-2.69 to 0.81) | -1.2 (-2.96 to 0.54) |
| Change at 2 hours post-dose | -0.5 (-1.97 to 0.99) | -0.5 (-1.94 to 1.01) |
| Change at 2.5 hours post-dose | -3.9 (-5.82 to -2.02) | -0.8 (-2.73 to 1.06) |
| Change at 3 hours post-dose | -0.9 (-2.87 to 1.13) | -1.3 (-3.30 to 0.70) |
| Change at 4 hours post-dose | -1.6 (-3.23 to 0.05) | -2.3 (-3.91 to -0.64) |
| Change at 6 hours post-dose | -4.4 (-6.12 to -2.73) | -2.7 (-4.34 to -0.96) |
| Change at 8.5 hours post-dose | -6.2 (-8.30 to -4.06) | -5.1 (-7.24 to -3.00) |
| Change at 12 hours post-dose | -4.9 (-7.82 to -1.88) | -2.8 (-5.77 to 0.17) |
| Change at 24 hours post-dose | -4.2 (-6.59 to -1.75) | -0.6 (-3.11 to 1.90) |
QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Change from baseline in QRS intervals (Δ QRS) was calculated using linear mixed-effects model analysis.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: Pirtobrutinib Matched Placebo |
|---|---|---|
| Change at 0.25 hour post-dose | 0.0 (-0.24 to 0.24) | 0.0 (-0.26 to 0.22) |
| Change at 0.5 hour post-dose | 0.2 (-0.03 to 0.45) | -0.1 (-0.37 to 0.11) |
| Change at 0.75 hour post-dose | 0.2 (-0.01 to 0.42) | 0.0 (-0.18 to 0.25) |
| Change at 1 hour post-dose | 0.2 (-0.18 to 0.49) | -0.1 (-0.43 to 0.22) |
| Change at 1.5 hours post-dose | -0.1 (-0.34 to 0.17) | -0.1 (-0.35 to 0.15) |
| Change at 2 hours post-dose | 0.0 (-0.29 to 0.20) | -0.1 (-0.33 to 0.16) |
| Change at 2.5 hours post-dose | -0.1 (-0.39 to 0.18) | -0.1 (-0.41 to 0.15) |
| Change at 3 hours post-dose | 0.2 (-0.06 to 0.50) | -0.1 (-0.38 to 0.18) |
| Change at 4 hours post-dose | 0.2 (-0.13 to 0.44) | 0.1 (-0.19 to 0.37) |
| Change at 6 hours post-dose | 0.7 (0.30 to 1.01) | 0.2 (-0.19 to 0.52) |
| Change at 8.5 hours post-dose | -0.6 (-1.17 to -0.12) | 0.1 (-0.42 to 0.63) |
| Change at 12 hours post-dose | 0.4 (-0.11 to 0.83) | 0.3 (-0.16 to 0.78) |
| Change at 24 hours post-dose | 0.2 (-0.81 to 1.23) | -1.0 (-2.03 to 0.10) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: Pirtobrutinib Matched Placebo |
|---|---|---|
| Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔQTcS), If a Substantial Heart Rate Effect Was Observed | NA (NA to NA) | NA (NA to NA) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: Pirtobrutinib Matched Placebo |
|---|---|---|
| Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔQTcI), If a Substantial Heart Rate Effect Was Observed | NA (NA to NA) | NA (NA to NA) |
Heart rate is the number of times the ventricles of the heart contract and relax per minute. Placebo-corrected change from baseline in heart rate (ΔΔHR) was calculated using linear mixed-effects model analysis.
| beats/min | Treatment A: 900 mg Pirtobrutinib | Treatment C: 400 mg Moxifloxacin |
|---|---|---|
| Change at 0.25 hours post-dose | 0.9 (-0.11 to 1.96) | 0.1 (-0.92 to 1.15) |
| Change at 0.5 hours post-dose | 0.6 (-0.65 to 1.90) | 3.0 (1.71 to 4.27) |
| Change at 0.75 hours post-dose | 0.4 (-1.06 to 1.91) | 3.8 (2.35 to 5.34) |
| Change at 1 hour post-dose | 1.2 (-0.33 to 2.68) | 4.2 (2.71 to 5.71) |
| Change at 1.5 hours post-dose | 2.6 (1.26 to 3.92) | 2.8 (1.43 to 4.10) |
| Change at 2 hours post-dose | 1.3 (-0.18 to 2.77) | 2.5 (1.02 to 3.99) |
| Change at 2.5 hours post-dose | 2.3 (0.66 to 3.90) | 2.9 (1.25 to 4.53) |
| Change at 3 hours post-dose | 0.9 (-0.63 to 2.38) | 1.1 (-0.38 to 2.65) |
| Change at 4 hours post-dose | 1.0 (-0.51 to 2.53) | 1.9 (0.34 to 3.40) |
| Change at 6 hours post-dose | 1.6 (-0.14 to 3.28) | 2.6 (0.86 to 4.32) |
| Change at 8.5 hours post-dose | 0.6 (-1.47 to 2.58) | 1.5 (-0.54 to 3.54) |
| Change at 12 hours post-dose | 1.6 (-0.68 to 3.91) | 4.5 (2.16 to 6.82) |
| Change at 24 hours post-dose | 0.4 (-1.06 to 1.91) | 1.0 (-0.47 to 2.54) |
Pulse rate is number of times heart beats per minute. Pulse rate measurements were performed using the same arm for each reading and measurements were taken after the participant had been resting in the supine position for at least 5 minutes. Placebo-corrected change from baseline in pulse rate (ΔPR) was calculated using linear mixed-effects model analysis.
| beats/min | Treatment A: 900 mg Pirtobrutinib | Treatment C: 400 mg Moxifloxacin |
|---|---|---|
| Change at 0.25 hours post-dose | -1.9 (-4.28 to 0.56) | -1.2 (-3.65 to 1.24) |
| Change at 0.5 hours post-dose | -1.2 (-3.72 to 1.33) | -2.1 (-4.68 to 0.42) |
| Change at 0.75 hours post-dose | -0.7 (-2.93 to 1.55) | -2.5 (-4.80 to -0.27) |
| Change at 1 hours post-dose | -0.7 (-3.69 to 2.20) | -3.8 (-6.78 to -0.88) |
| Change at 1.5 hours post-dose | 0.3 (-2.05 to 2.60) | -3.4 (-5.78 to -1.09) |
| Change at 2 hours post-dose | 0.0 (-1.94 to 1.89) | -3.6 (-5.54 to -1.68) |
| Change at 2.5 hours post-dose | -3.1 (-5.64 to -0.54) | -4.6 (-7.23 to -2.05) |
| Change at 3 hours post-dose | 0.4 (-2.27 to 3.13) | -4.0 (-6.70 to -1.26) |
| Change at 4 hours post-dose | 0.7 (-1.47 to 2.85) | -4.2 (-6.33 to -1.98) |
| Change at 6 hours post-dose | -1.8 (-4.01 to 0.47) | -4.3 (-6.53 to -2.02) |
| Change at 8.5 hours post-dose | -1.1 (-3.94 to 1.82) | -2.1 (-5.00 to 0.80) |
| Change at 12 hours post-dose | -2.1 (-6.17 to 2.06) | -3.5 (-7.63 to 0.71) |
| Change at 24 hours post-dose | -3.6 (-6.95 to -0.18) | -0.8 (-4.19 to 2.69) |
QRS interval in an ECG measured the total time of ventricular depolarization. It begins with Q or R wave and ends at the end of the S wave. Placebo-corrected change from baseline in QRS intervals (ΔΔQRS) was calculated using linear mixed-effects model analysis.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment C: 400 mg Moxifloxacin |
|---|---|---|
| Change at 0.25 hours post-dose | 0.0 (-0.32 to 0.36) | -0.3 (-0.63 to 0.06) |
| Change at 0.5 hours post-dose | 0.3 (0.00 to 0.68) | 0.1 (-0.26 to 0.43) |
| Change at 0.75 hours post-dose | 0.2 (-0.13 to 0.47) | 0.3 (0.03 to 0.63) |
| Change at 1 hours post-dose | 0.3 (-0.21 to 0.73) | 0.1 (-0.34 to 0.59) |
| Change at 1.5 hours post-dose | 0.0 (-0.34 to 0.37) | 0.1 (-0.22 to 0.49) |
| Change at 2 hours post-dose | 0.0 (-0.30 to 0.39) | 0.1 (-0.20 to 0.50) |
| Change at 2.5 hours post-dose | 0.0 (-0.37 to 0.43) | 0.1 (-0.33 to 0.48) |
| Change at 3 hours post-dose | 0.3 (-0.07 to 0.72) | -0.1 (-0.50 to 0.29) |
| Change at 4 hours post-dose | 0.1 (-0.33 to 0.46) | -0.3 (-0.67 to 0.13) |
| Change at 6 hours post-dose | 0.5 (-0.01 to 0.99) | -0.1 (-0.58 to 0.43) |
| Change at 8.5 hours post-dose | -0.8 (-1.50 to -0.01) | -0.4 (-1.12 to 0.38) |
| Change at 12 hours post-dose | 0.1 (-0.62 to 0.72) | 0.0 (-0.65 to 0.70) |
| Change at 24 hours post-dose | 1.2 (-0.30 to 2.65) | 0.2 (-1.25 to 1.74) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcF.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Placebo-corrected Change From Baseline in ΔQTcF (ΔΔQTcF), If a Substantial Heart Rate Effect Was Observed | NA (NA to NA) | NA (NA to NA) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcS.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Placebo-corrected Change From Baseline in Individualized Heart Rate-Corrected QT Interval (ΔΔQTcS), If a Substantial Heart Rate Effect Was Observed | NA (NA to NA) | NA (NA to NA) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. The QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole. QT interval was corrected for heart rate using QTcI.
| msec | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Placebo-corrected Change From Baseline in Optimized Heart Rate-Corrected QT Interval (ΔΔQTcI), If a Substantial Heart Rate Effect Was Observed | NA (NA to NA) | NA (NA to NA) |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with potentially clinically significant ECG changes were reported.
| Participants | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Changes | 0 | 0 |
The cardiodynamic assessment was performed through 12-lead ECG extracted from continuous recordings at pre-specified time points. Participants rested in supine position for at least 10 minutes prior to and 5 minutes after each time point for ECG extractions. Number of participants with treatment emergent changes in T-wave morphology and U-wave presence were reported.
| Participants | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo |
|---|---|---|
| Treatment Emergent Changes in T-wave Morphology | 0 | 0 |
| Treatment Emergent Changes in U-wave Presence | 0 | 0 |
PK: %AUCextrap was defined as percentage extrapolation for AUC0-inf.
| percentage of AUC | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| Pharmacokinetic (PK): Percentage of AUC0-inf Extrapolated (AUC%Extrap) of Pirtobrutinib | 5.41 ± 42.0 |
PK: MRT was calculated by the area under the first moment curve divided by the area under the concentration time curve.
| hours | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Mean Residence Time (MRT) of Pirtobrutinib | 33.6 ± 14.6 |
PK: Vz/F was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.
| liter | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib | 62.1 ± 22.5 |
PK: Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for pirtobrutinib.
| hours | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib | 4.01 (3.00 to 24.0) |
PK: t1/2 was defined as the terminal elimination phase half-life for pirtobrutinib.
| hours | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Apparent Plasma Terminal Elimination Half-life (t1/2) of Pirtobrutinib | 23.0 ± 14.5 |
PK: Cmax was defined as the maximum plasma concentration for pirtobrutinib.
| nanogram per milliliter (ng/mL) | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib | 14300 ± 23.1 |
PK: AUC(0-24) was defined as the area under the plasma concentration-time curve from 0 time to 24 hours post-dose.
| hour*nanogram per milliliter (h*ng/mL) | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib | 229000 ± 17.5 |
PK: AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for pirtobrutinib.
| h*ng/mL | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib | 452000 ± 20.7 |
PK: Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.
| liter per hour (L/h) | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib | 1.88 ± 21.4 |
PK: AUC(0-inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for pirtobrutinib.
| h*ng/mL | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib | 480000 ± 21.4 |
PK: Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.
| one per hour (1/h) | Treatment A: 900 mg Pirtobrutinib |
|---|---|
| Participant 1 | 0.0320 |
| Participant 2 | 0.0270 |
| Participant 3 | 0.0356 |
| Participant 4 | 0.0259 |
| Participant 5 | 0.0270 |
| Participant 6 | 0.0330 |
| Participant 7 | 0.0310 |
| Participant 8 | 0.0331 |
| Participant 9 | 0.0353 |
| Participant 10 | 0.0322 |
| Participant 11 | 0.0271 |
| Participant 12 | 0.0213 |
| Participant 13 | 0.0337 |
| Participant 14 | 0.0273 |
| Participant 15 | 0.0229 |
| Participant 16 | 0.0314 |
| Participant 17 | 0.0364 |
| Participant 18 | 0.0289 |
| Participant 19 | 0.0309 |
| Participant 20 | 0.0271 |
| Participant 21 | 0.0269 |
| Participant 22 | 0.0422 |
| Participant 23 | 0.0346 |
| Participant 24 | 0.0273 |
| Participant 25 | 0.0288 |
| Participant 26 | 0.0306 |
| Participant 27 | 0.0364 |
| Participant 28 | 0.0299 |
| Participant 29 | 0.0304 |
| Participant 30 | 0.0283 |
Collected over Baseline up to follow-up (up to Day 42). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: 900 mg Pirtobrutinib | 0/30 (0%) | 0/30 (0%) | 6/30 (20%) |
| Treatment B: 900 mg Pirtobrutinib Matched Placebo | 0/31 (0%) | 0/31 (0%) | 1/31 (3.2%) |
| Treatment C: 400 mg Moxifloxacin | 0/30 (0%) | 0/30 (0%) | 1/30 (3.3%) |
| Event | Treatment A: 900 mg Pirtobrutinib | Treatment B: 900 mg Pirtobrutinib Matched Placebo | Treatment C: 400 mg Moxifloxacin |
|---|---|---|---|
| HeadacheNervous system disorders | 5/30 | 1/31 | 1/30 |
| DiarrhoeaGastrointestinal disorders | 2/30 | 0/31 | 0/30 |
All participants who received 1 dose of study drug.
| Age, Continuous(years) | Treatment Sequence: ABC | Treatment Sequence: BCA | Treatment Sequence: CAB | Treatment Sequence: ACB | Treatment Sequence: CBA | Treatment Sequence: BAC | Total |
|---|---|---|---|---|---|---|---|
| Mean | 35.0 ± 9.87 | 39.0 ± 8.81 | 37.8 ± 7.95 | 35.6 ± 7.86 | 34.4 ± 6.77 | 38.2 ± 10.01 | 36.7 ± 8.08 |
| Sex: Female, Male(Participants) | Treatment Sequence: ABC | Treatment Sequence: BCA | Treatment Sequence: CAB | Treatment Sequence: ACB | Treatment Sequence: CBA | Treatment Sequence: BAC | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 0 | 0 | 2 | 7 |
| Male | 4 | 4 | 3 | 5 | 5 | 3 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence: ABC | Treatment Sequence: BCA | Treatment Sequence: CAB | Treatment Sequence: ACB | Treatment Sequence: CBA | Treatment Sequence: BAC | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 | 1 | 3 | 8 |
| Not Hispanic or Latino | 4 | 6 | 4 | 3 | 4 | 2 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence: ABC | Treatment Sequence: BCA | Treatment Sequence: CAB | Treatment Sequence: ACB | Treatment Sequence: CBA | Treatment Sequence: BAC | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 4 | 4 | 2 | 1 | 1 | 2 | 14 |
| White | 0 | 2 | 3 | 3 | 3 | 3 | 14 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Treatment Sequence: ABC | Treatment Sequence: BCA | Treatment Sequence: CAB | Treatment Sequence: ACB | Treatment Sequence: CBA | Treatment Sequence: BAC | Total |
|---|---|---|---|---|---|---|---|
| United States | 5 | 6 | 5 | 5 | 5 | 5 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Mar 2021, 3 months.
Results were first posted in Feb 2025, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib